Log in

Relevant bibliographies by topics / Sucrosomial iron

Contents

Journal articles
Dissertations / Theses

Academic literature on the topic 'Sucrosomial iron'

Author: Grafiati

Published: 9 March 2023

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sucrosomial iron.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sucrosomial iron"

1

Asperti, Michela, Magdalena Gryzik, Elisa Brilli, et al. "Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation." Nutrients 10, no. 10 (2018): 1349. http://dx.doi.org/10.3390/nu10101349.

Full text

Abstract:

Sucrosomial® Iron is a recently developed formulation to treat iron deficiency based on ferric pyrophosphate covered by a matrix of phospholipids plus sucrose esters of fatty acids. Previous data indicated that Sucrosomial® Iron is efficiently absorbed by iron-deficient subjects, even at low dosage, and without side effects. Its structural properties may suggest that it is absorbed by an intestinal pathway which is different to the one used by ionic iron. Although, studies in vitro showed that Sucrosomial® Iron is readily absorbed, no animal models have been established to study this important

APA, Harvard, Vancouver, ISO, and other styles

2

Brilli, Elisa, Maura Poli, Asperti Michela, et al. "Effects of Sucrosomial® iron in Pre-Clinical and Clinical Conditions of Inflammation." Blood 130, Suppl_1 (2017): 942. http://dx.doi.org/10.1182/blood.v130.suppl_1.942.942.

Full text

Abstract:

Abstract Introduction: Proteins such as Ferritin (Ft), Hemoglobin (Hb) and Transferrin Receptor (TfR1) are involved in tissue iron distribution while systemiciron metabolism is regulated by Hepcidin. Interleukin-6 (IL-6) release is induced in response to an inflammatory status and enhances Hepcidin expression, as consequence, dietary iron absorption and macrophage iron recycling are inhibited. Anemia of Chronic Disease (ACD) is a form of anemia associated with many different chronic disorders. It is characterized by high hepcidin and CRP or IL-6 expression and low serum iron transferrin concen

APA, Harvard, Vancouver, ISO, and other styles

3

Brilli, Elisa, Michela Asperti, Annalisa Castagna, et al. "Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model." Blood 134, Supplement_1 (2019): 2235. http://dx.doi.org/10.1182/blood-2019-122416.

Full text

Abstract:

Introduction: Iron Refractory Iron Deficiency Anemia (IRIDA) is an autosomal recessive iron metabolism disorder caused by mutations in Tmprss6 gene which encodes for Matriptase2 (MT2) that, by activating hemojuvelin (HJV), regulates the production of hepcidin, the master iron regulatory hormone. Altered MT2 cannot suppress hepatic BMP6/SMAD signaling in low iron condition, hence the resulting hepcidin excess blocks dietary iron absorption and cells release, leading to a form of iron deficiency that is typically refractory to oral iron supplementation. IRIDA is characterized by moderate/severe

APA, Harvard, Vancouver, ISO, and other styles

4

Giordano, Giulio, Marco Alfio Cutuli, Alessandro Lucchesi, et al. "Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting." Acta Haematologica 143, no. 2 (2019): 155–62. http://dx.doi.org/10.1159/000501329.

Full text

Abstract:

Refractory anaemia (RA) among myelodysplastic syndrome (MDS) is associated with a partial functional iron deficit and may require transfusions. In low-risk lymphoma and solid tumour patients, iron support improves erythropoietin (EPO) cost-effectiveness in treating anaemia. The aim of this study is to see if oral sucrosomial iron support improves the cost-effectiveness of EPO treatment in MDS patients affected by low-risk RA. We treated patients with EPO only or with EPO plus oral sucrosomial iron or intravenous (i.v.) iron. The need for transfusions was lowest in the group taking oral iron (p

APA, Harvard, Vancouver, ISO, and other styles

5

Zakrzewski, Martha, Sarah J. Wilkins, Sheridan L. Helman, et al. "Supplementation with Sucrosomial® iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice." BioMetals 35, no. 1 (2021): 27–38. http://dx.doi.org/10.1007/s10534-021-00348-3.

Full text

Abstract:

AbstractIron deficiency is one of the most common nutritional deficiencies worldwide and is often treated with oral iron supplements. However, commonly used supplements, including those based on ferrous iron salts, are associated with gastrointestinal side effects and unfavorable changes in the intestinal microbiome. Sucrosomial® iron is a novel iron formulation that is effective at treating iron deficiency, and with fewer gastrointestinal side effects, yet its effect on the gut microbiome has not been examined previously. Thus, we treated mice for two weeks with diets containing either Sucros

APA, Harvard, Vancouver, ISO, and other styles

6

Tarantino, Germano, Elisa Brilli, Giulio Giordano, Alessandro Torelli, and Francesco Equitani. "Innovative Oral Iron Supplement (Sucrosomial Iron®) Is Able to Downregulate Hepcidin Release during Inflammation: In Vitro Study." Blood 126, no. 23 (2015): 4563. http://dx.doi.org/10.1182/blood.v126.23.4563.4563.

Full text

Abstract:

Abstract Introduction: the involvement of iron in a wide range of metabolic processes make it one of the essential elements for living organisms (Inamura et al., 2005). Anemia of chronic disease (ACD), also termed anemia of chronic inflammation, is the most prevalent anemia in subjects suffering from chronic diseases such as cancer and Chronic Kidney Disease (CKD). A central mechanism by which chronic disease causes anemia is the retention of iron in the reticuloendothelial system, causing a functional iron deficiency and consequently an insufficient iron supply for erythropoiesis. Hepcidin is

APA, Harvard, Vancouver, ISO, and other styles

7

Brilli, Elisa, Alessandra Romano, Angela Fabiano, Ylenia Zambito, Francesco Di Raimondo, and Germano Tarantino. "Sucrosomial Technology Is Able to Promote Ferric Iron Absorption: Pre-Clinical and Clinical Evidences." Blood 128, no. 22 (2016): 3618. http://dx.doi.org/10.1182/blood.v128.22.3618.3618.

Full text

Abstract:

Abstract Introduction: Oral iron delivery is attractive due to the ease of administration and is mainly based on immediate release formulations of ferrous iron. Commonly used ferrous iron salts are poorly absorbed. Overcoming gastrointestinal barriers, is a great challenge and there is a need for new absorption and protective enhancers. Iron DeficiencyAnemia (IDA) is a presenting symptom in approximately 40% of patients with Hodgkin's Lymphoma (HL). Usually with hemoglobin (Hb) between 10 and 12 g/dL. When considering oral iron therapy in cancer patients one must take into account the impact o

APA, Harvard, Vancouver, ISO, and other styles

8

Tarantino, Germano, Elisa Brilli, Ylenia Zambito, Giulio Giordano, and Francesco Equitani. "Sucrosomial Iron®: A New Highly Bioavaible Oral Iron Supplement." Blood 126, no. 23 (2015): 4561. http://dx.doi.org/10.1182/blood.v126.23.4561.4561.

Full text

Abstract:

Abstract Introduction: Iron deficiency is one of the most widespread nutritional deficiencies. Globally two billion people are suffering from iron- deficiency anemia (Hermida et al., 2010). Oral therapy for iron deficiency is mainly based on immediate release formulations of ferrous iron. However, modified formulations have been marketed to reduce gastrointestinal side effects and to prevent iron instability in the gastrointestinal tract. Overcoming biological barriers, including the gastrointestinal epithelial barriers, is a great challenge for pharmaceutical research and thus there is a need

APA, Harvard, Vancouver, ISO, and other styles

9

Szudzik, Mateusz, Rafał Starzyński, Aneta Jończy, Rafał Mazgaj, Małgorzata Lenartowicz, and Paweł Lipiński. "Correction: Mateusz, S., et al. Iron Supplementation in Suckling Piglets: An Ostensibly Easy Therapy of Neonatal Iron Deficiency Anemia. Pharmaceuticals 2018, 11, 128." Pharmaceuticals 12, no. 1 (2019): 22. http://dx.doi.org/10.3390/ph12010022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gómez-Ramírez, Susana, Elisa Brilli, Germano Tarantino, and Manuel Muñoz. "Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation." Pharmaceuticals 11, no. 4 (2018): 97. http://dx.doi.org/10.3390/ph11040097.

Full text

Abstract:

Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced treatment compliance. Intravenous (IV) iron formulations are increasingly safer, but there is still a risk of infusion and hypersensitivity reactions and the need for a venous access and infusion monitoring. Sucrosomial® iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Sucrosomial iron"

1

ASTORI, EMANUELA. "IN VITRO AND IN VIVO APPROACHES TO STUDY OXIDATIVE STRESS, ANEMIA AND DYSBIOSIS IN CHRONIC KIDNEY DISEASE." Doctoral thesis, Università degli Studi di Milano, 2021. http://hdl.handle.net/2434/818976.

Full text

Abstract:

CKD is diagnosed when there’s a decreased kidney function shown by a GFR less than 60 ml / min (established for a reference man with 1.73 m² body surface area), or markers of kidney damage, or both, of at least 3 months duration. The severity of complications increases in parallel with the GFR decline. We focused on three comorbidities extremely common in CKD patients: oxidative stress and inflammation; anemia and dysbiosis. We investigated these CKD comorbidities both with in vitro and in vivo approaches. More in detail, regarding in vivo studies, we measured oxidative stress biomarkers in a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!